In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.
The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.
It took place on 14 Dec, 4PM GMT, 5PM CET.
Watch on Demand for free here.
Dr. Christoph Herbel is a Team Coordinator in the Research and Development department at Miltenyi Biotec where he characterises new targets for immune cell–based cancer therapy using the MACSima Imaging Platform.
To assess the safety profile of potential CAR targets, Dr. Herbel’s team analysed the marker expression across many healthy human tissues using high-content imaging on the MACSima Imaging Platform. They identified novel marker combinations for pancreatic ductal adenocarcinoma, glioblastoma, and ovarian carcinoma as candidates for combinatorial CAR T cell therapy. Using Adapter CAR Technology, they tested the functionality of the novel target candidates for ovarian cancer in vitro – with intriguing results.
